Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation

HOUSTON, March 13, 2023 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it is aware that the…

Leave a Reply

Your email address will not be published. Required fields are marked *